Cargando…

Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion

The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retina...

Descripción completa

Detalles Bibliográficos
Autores principales: Michalska-Małecka, Katarzyna, Gaborek, Aneta, Nowak, Mariusz, Halat, Tomasz, Pawłowska, Mariola, Śpiewak, Dorota
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887062/
https://www.ncbi.nlm.nih.gov/pubmed/27307716
http://dx.doi.org/10.2147/CIA.S96674
_version_ 1782434691201105920
author Michalska-Małecka, Katarzyna
Gaborek, Aneta
Nowak, Mariusz
Halat, Tomasz
Pawłowska, Mariola
Śpiewak, Dorota
author_facet Michalska-Małecka, Katarzyna
Gaborek, Aneta
Nowak, Mariusz
Halat, Tomasz
Pawłowska, Mariola
Śpiewak, Dorota
author_sort Michalska-Małecka, Katarzyna
collection PubMed
description The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety outcomes were intraocular pressure and cornea endothelial cell density. The study was conducted by the prospective analysis on 36 patients (17 women and 19 men) aged 28–77 years (the average age was 58±15 years) treated with the injection of dexamethasone implant because of the persistent ME at the Department of Ophthalmology and Ophthalmology Outpatient Clinic of the University Centre of Ophthalmology and Oncology in Katowice. The studied group included 16 patients with central retinal vein occlusion (16 eyes), and 20 patients with branch retinal vein occlusion (20 eyes). We found a significant increase of BCVA after first, second, and third month of treatment. Six months after the treatment, BCVA decreased, although not significantly compared with the value obtained in the third month. Two months after the intravitreal implantation of dexamethasone delivery system, CRT was 338±163 μm and was significantly lower compared with pretreatment value. Between third and sixth month after the treatment, we found insignificant increase of CRT compared with thickness observed in second month. Two months after the treatment, we found an increase in intraocular pressure in 36% of cases and a further decrease during the final visit 6 months after the treatment. During the treatment, there were no significant differences in endothelial cell density in branch retinal vein occlusion and central retinal vein occlusion. We found the intravitreal dexamethasone implant to be safe, well tolerated, and likely to lead to fast morphological and functional improvement of the macula and visual rehabilitation in patients with ME due to retinal vein occlusion.
format Online
Article
Text
id pubmed-4887062
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48870622016-06-15 Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion Michalska-Małecka, Katarzyna Gaborek, Aneta Nowak, Mariusz Halat, Tomasz Pawłowska, Mariola Śpiewak, Dorota Clin Interv Aging Original Research The purpose of this study was to evaluate the impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and functions in eyes with macular edema (ME) secondary to retinal vein occlusion. Efficacy outcomes of the treatment were best-corrected visual acuity (BCVA) and central retinal thickness (CRT). Safety outcomes were intraocular pressure and cornea endothelial cell density. The study was conducted by the prospective analysis on 36 patients (17 women and 19 men) aged 28–77 years (the average age was 58±15 years) treated with the injection of dexamethasone implant because of the persistent ME at the Department of Ophthalmology and Ophthalmology Outpatient Clinic of the University Centre of Ophthalmology and Oncology in Katowice. The studied group included 16 patients with central retinal vein occlusion (16 eyes), and 20 patients with branch retinal vein occlusion (20 eyes). We found a significant increase of BCVA after first, second, and third month of treatment. Six months after the treatment, BCVA decreased, although not significantly compared with the value obtained in the third month. Two months after the intravitreal implantation of dexamethasone delivery system, CRT was 338±163 μm and was significantly lower compared with pretreatment value. Between third and sixth month after the treatment, we found insignificant increase of CRT compared with thickness observed in second month. Two months after the treatment, we found an increase in intraocular pressure in 36% of cases and a further decrease during the final visit 6 months after the treatment. During the treatment, there were no significant differences in endothelial cell density in branch retinal vein occlusion and central retinal vein occlusion. We found the intravitreal dexamethasone implant to be safe, well tolerated, and likely to lead to fast morphological and functional improvement of the macula and visual rehabilitation in patients with ME due to retinal vein occlusion. Dove Medical Press 2016-05-23 /pmc/articles/PMC4887062/ /pubmed/27307716 http://dx.doi.org/10.2147/CIA.S96674 Text en © 2016 Michalska-Małecka et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Michalska-Małecka, Katarzyna
Gaborek, Aneta
Nowak, Mariusz
Halat, Tomasz
Pawłowska, Mariola
Śpiewak, Dorota
Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title_full Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title_fullStr Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title_full_unstemmed Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title_short Evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
title_sort evaluation of the effectiveness and safety of glucocorticoids intravitreal implant therapy in macular edema due to retinal vein occlusion
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887062/
https://www.ncbi.nlm.nih.gov/pubmed/27307716
http://dx.doi.org/10.2147/CIA.S96674
work_keys_str_mv AT michalskamałeckakatarzyna evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion
AT gaborekaneta evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion
AT nowakmariusz evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion
AT halattomasz evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion
AT pawłowskamariola evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion
AT spiewakdorota evaluationoftheeffectivenessandsafetyofglucocorticoidsintravitrealimplanttherapyinmacularedemaduetoretinalveinocclusion